Pfizer Inc. $PFE Shares Sold by Emerald Advisors LLC

Key Points

• Emerald Advisors LLC significantly reduced its stake in Pfizer by 63.0%, selling 19,938 shares during the second quarter, which left them with 11,685 shares valued at $283,000.
• Other institutional investors, including Pacer Advisors Inc. and Amundi, increased their stakes in Pfizer, with Pacer Advisors growing its holdings by 856.8%.
• Pfizer reported $0.78 earnings per share for the last quarter, exceeding estimates, and set its FY 2025 guidance at 2.900-3.100 EPS.

Emerald Advisors LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 63.0% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,685 shares of the biopharmaceutical company's stock after selling 19,938 shares during the quarter. Emerald Advisors LLC's holdings in Pfizer were worth $283,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of PFE. Pacer Advisors Inc. grew its holdings in Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after buying an additional 17,957,928 shares during the last quarter. Amundi grew its holdings in Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after buying an additional 15,758,846 shares during the last quarter. Nuveen LLC acquired a new stake in Pfizer during the 1st quarter valued at $389,861,000. Goldman Sachs Group Inc. grew its holdings in Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after buying an additional 9,041,990 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after buying an additional 7,581,030 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Up 0.3%

Shares of PFE opened at $23.84 on Tuesday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The firm has a market capitalization of $135.54 billion, a P/E ratio of 12.68, a price-to-earnings-growth ratio of 0.77 and a beta of 0.55. The stock's fifty day simple moving average is $24.54 and its 200 day simple moving average is $24.11. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business's quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a report on Sunday. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.